Clincosm LogoSign in Get a demo

primary central nervous system lymphoma

Showing 1 - 25 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Completed
  • Primary Central Nervous System Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

Primary CNS Lymphoma Trial in Worldwide (Rituximab, Methotrexate, Procarbazine)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Aarhus, Denmark
  • +34 more
Nov 4, 2022

Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié-Salpêtrière
Oct 24, 2022

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib,Rituximab and Methotrexate
  • Beijing, Beijing, China
    Hospital 307
Sep 19, 2022

Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier Trial in Worldwide (CC-122)

Active, not recruiting
  • Multiple Myeloma
  • +5 more
  • Duarte, California
  • +38 more
Aug 18, 2022

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

Recruiting
  • Primary Central Nervous System Lymphoma
  • the dose-escalation phase
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
May 30, 2022

Primary CNS Lymphoma Trial in Paris (PET-MRI)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié Salpêtrière
May 20, 2022

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, Beijing, China
  • +2 more
May 19, 2022

Primary CNS Lymphoma Trial (Penpulimab)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • (no location specified)
Apr 20, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 18, 2022

Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
Apr 6, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 14, 2022

Primary CNS Lymphoma Trial in Stuttgart (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix,

Recruiting
  • Primary Central Nervous System Lymphoma
  • Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
  • Control intervention: four courses of MATRix
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Feb 15, 2022

Primary CNS Lymphoma Trial in Paris (Rituximab, Methotrexate, Temozolomide)

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Rituximab, Methotrexate, Temozolomide
  • Paris, France
    Groupe Hospitalier Pitie Salpetriere
Feb 10, 2022

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

Primary CNS Lymphoma Trial in Paris ([18F]-FDG PET/MR)

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • [18F]-FDG PET/MR
  • Paris, France
    Pitié Salpêtrière Hospital
Sep 9, 2021

Primary CNS Lymphoma Trial in Beijing (orelabrutinib, Sintilimab, Tislelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Wei Zhang
May 19, 2021

Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy

Recruiting
  • Primary Central Nervous System Lymphoma
  • Standard treatment protocol with combined chemoradiation
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital
Mar 9, 2021